Tino F Schwarz

Summary

Affiliation: Stiftung Juliusspital
Country: Germany

Publications

  1. ncbi Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature
    Tino F Schwarz
    Central Laboratory and Vaccination Centre, Stiftung Juliusspital Würzburg, Juliuspromenade 19, 97070 Wurzburg, Germany
    Gynecol Oncol 110:S1-10. 2008
  2. ncbi Assessment of functional antibacterial opsonophagocytic antibodies elicited by 13-valent pneumococcal conjugate vaccine administered concomitantly with trivalent influenza vaccine in a randomized clinical trial in adults aged ≥65 years
    Tino F Schwarz
    Central Laboratory and Vaccination Centre, Stiftung Juliusspital, Juliuspromenade 19, 97070 Wurzburg, Germany
    Vaccine 31:291-4. 2013
  3. ncbi Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years
    Tino F Schwarz
    Central Laboratory and Vaccination Centre, Stiftung Juliusspital Wuerzburg, Wuerzburg, Germany
    J Adolesc Health 50:187-94. 2012
  4. ncbi Intracellular localization of Crimean-Congo Hemorrhagic Fever (CCHF) virus glycoproteins
    Sebastian Haferkamp
    University of Texas Medical Branch, Department of Pathology, Center for Biodefense and Emerging Infectious Diseases, 301 University Boulevard, Galveston 77555 0609, USA
    Virol J 2:42. 2005
  5. ncbi Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years
    Tino F Schwarz
    Central Laboratory and Vaccination Centre, Stiftung Juliusspital Würzburg, Germany
    Hum Vaccin 7:958-65. 2011
  6. ncbi A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years
    T F Schwarz
    Central Laboratory and Vaccination Centre, Stiftung Juliusspital, Wurzburg, Germany
    Vaccine 29:5195-202. 2011
  7. ncbi Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine
    Tino F Schwarz
    Central Laboratory and Vaccination Centre, Stiftung Juliusspital, Wuerzburg, Germany
    Hum Vaccin 6:1054-61. 2010
  8. ncbi Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix
    Tino F Schwarz
    Central Laboratory and Vaccination Centre, Stiftung Juliusspital Würzburg, Germany
    Adv Ther 26:983-98. 2009
  9. ncbi Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults
    Tino F Schwarz
    Stiftung Juliusspital, Körperschaft des öffentlichen Rechts, Juliuspromenade 19, 97070 Wurzburg, Germany
    Vaccine 27:6284-90. 2009
  10. ncbi AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention
    Tino F Schwarz
    Central Laboratory and Vaccination Center, Stiftung Juliusspital, Academic Teaching Hospital of the University of Wuerzburg, Juliuspromenade 19, D 97070 Wuerzburg, Germany
    Expert Rev Vaccines 7:1465-73. 2008

Collaborators

Detail Information

Publications16

  1. ncbi Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature
    Tino F Schwarz
    Central Laboratory and Vaccination Centre, Stiftung Juliusspital Würzburg, Juliuspromenade 19, 97070 Wurzburg, Germany
    Gynecol Oncol 110:S1-10. 2008
    ..These immunological effects represent the basis for the protection afforded by the AS04-adjuvanted HPV-16/18 vaccine and its observed long-term efficacy against development of precancerous lesions to prevent cervical cancer...
  2. ncbi Assessment of functional antibacterial opsonophagocytic antibodies elicited by 13-valent pneumococcal conjugate vaccine administered concomitantly with trivalent influenza vaccine in a randomized clinical trial in adults aged ≥65 years
    Tino F Schwarz
    Central Laboratory and Vaccination Centre, Stiftung Juliusspital, Juliuspromenade 19, 97070 Wurzburg, Germany
    Vaccine 31:291-4. 2013
    ..Concomitant use of PCV13 and TIV should therefore be guided by clinical circumstances...
  3. ncbi Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years
    Tino F Schwarz
    Central Laboratory and Vaccination Centre, Stiftung Juliusspital Wuerzburg, Wuerzburg, Germany
    J Adolesc Health 50:187-94. 2012
    ..Long-term immunogenicity and safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine when administered to adolescent girls was evaluated...
  4. ncbi Intracellular localization of Crimean-Congo Hemorrhagic Fever (CCHF) virus glycoproteins
    Sebastian Haferkamp
    University of Texas Medical Branch, Department of Pathology, Center for Biodefense and Emerging Infectious Diseases, 301 University Boulevard, Galveston 77555 0609, USA
    Virol J 2:42. 2005
    ..To better understand the CCHFV life cycle and explore potential intervention strategies, we studied the biosynthesis and intracellular targeting of the glycoproteins, which are encoded by the M genome segment...
  5. ncbi Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years
    Tino F Schwarz
    Central Laboratory and Vaccination Centre, Stiftung Juliusspital Würzburg, Germany
    Hum Vaccin 7:958-65. 2011
    ....
  6. ncbi A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years
    T F Schwarz
    Central Laboratory and Vaccination Centre, Stiftung Juliusspital, Wurzburg, Germany
    Vaccine 29:5195-202. 2011
    ..Concomitant PCV13+TIV demonstrates acceptable immunogenicity and safety compared with either agent given alone...
  7. ncbi Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine
    Tino F Schwarz
    Central Laboratory and Vaccination Centre, Stiftung Juliusspital, Wuerzburg, Germany
    Hum Vaccin 6:1054-61. 2010
    ..These CVS antibodies may play a role in the protective efficacy of this vaccine...
  8. ncbi Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix
    Tino F Schwarz
    Central Laboratory and Vaccination Centre, Stiftung Juliusspital Würzburg, Germany
    Adv Ther 26:983-98. 2009
    ..3 years after vaccination. This is associated with high efficacy and no breakthrough cases in the HPV-naïve population, and is the longest duration follow-up for safety, immunogenicity, and efficacy for any licensed HPV vaccine to date...
  9. ncbi Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults
    Tino F Schwarz
    Stiftung Juliusspital, Körperschaft des öffentlichen Rechts, Juliuspromenade 19, 97070 Wurzburg, Germany
    Vaccine 27:6284-90. 2009
    ....
  10. ncbi AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention
    Tino F Schwarz
    Central Laboratory and Vaccination Center, Stiftung Juliusspital, Academic Teaching Hospital of the University of Wuerzburg, Juliuspromenade 19, D 97070 Wuerzburg, Germany
    Expert Rev Vaccines 7:1465-73. 2008
    ..Further studies will reveal the full duration and extent of the immune response and protection induced by Cervarix in broad populations and age ranges of women...
  11. ncbi Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years
    Tino F Schwarz
    Stiftung Juliusspital Würzburg, Zentrallabor, Juliuspromenade 19, D 97070 Wurzburg, Germany
    Vaccine 27:581-7. 2009
    ..The HPV-16/18 AS04-adjuvanted vaccine induces a robust and persistent immune response in women >26 years of age and generates antibodies that transudate through the cervix epithelium...
  12. ncbi An assessment of prime-boost vaccination schedules with AS03A -adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults
    Paul Gillard
    GlaxoSmithKline Biologicals, Wavre, Belgium
    Influenza Other Respi Viruses 7:55-65. 2013
    ....
  13. ncbi Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial
    Hans C Rumke
    Vaxinostics BV, University Vaccine Center Rotterdam Nijmegen, Beursplein 37, PO Box 30142, 3001 DC Rotterdam, The Netherlands
    Vaccine 26:2378-88. 2008
    ..The safety and reactogenicity profile of the AS-H5N1 candidate vaccine can be considered clinically acceptable in the context of its use against pandemic influenza...
  14. ncbi [Impact of vaccination against oncogenic human papillomavirus on the incidence and mortality of cervical cancer in Germany]
    Achim Schneider
    Klinik für Gynäkologie und gynäkologische Onkologie, Charite, Berlin
    Med Klin (Munich) 102:515-23. 2007
    ..The study aims to evaluate the achievable long-term impact of HPV vaccination on invasive cervical cancer (ICC) incidence and mortality in Germany, a country with an opportunistic Pap screening program and suboptimal participation...
  15. ncbi TBE booster immunization according to the rapid immunization schedule: are 3-year booster intervals really necessary?
    Olaf Zent
    Chiron Vaccines, Marburg, Germany
    Vaccine 23:312-5. 2004
    ..To conclude, these results suggest that the administration of a further booster dose 3 years after the first one (according to current recommendations) does not seem to be necessary in this study population...
  16. ncbi TBE booster immunization in adults--first experience with a new tick-borne encephalitis (TBE) vaccine, free of protein-derived stabilizer
    Olaf Zent
    Chiron Vaccines, Marburg, Germany
    Int J Med Microbiol 293:134-8. 2004
    ..A long lasting immunity can be concluded from the strong immune response following the booster immunization...